UMN Pharma to Manufacture, Sell Protein Sciences' Flu Vaccine in Japan | GenomeWeb
NEW YORK (GenomeWeb News) – Protein Sciences has licensed its FluBiok recombinant influenza vaccine to Japanese biotech UMN Pharma to make and sell the product in that market.
 
Terms of the deal call for PSC to transfer technology to UMN, which will register, manufacture, market, and sell the vaccine in Japan for annual and pandemic use.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.